Table 1 Biodistribution of radioactivity in mice at 48 h after oral administration of [223Ra]RaCl2 with pretreatment of 5% glucose (control), InsP6, or Zn-InsP6.

From: Decreasing undesirable absorbed radiation to the intestine after administration of radium-223 dichloride for treatment of bone metastases

Tissue

Control

InsP6

Zn-InsP6

Blood

0.01 (0.01)

0.01 (0.00)

0.01 (0.00)

Liver

0.01 (0.00)

0.01 (0.01)

0.01 (0.00)

Kidney

0.09 (0.03)

0.14 (0.03)

0.08 (0.05)

Small-intestine†

0.10 (0.09)

0.08 (0.02)

0.05 (0.04)

Large-intestine†

0.28 (0.22)

0.11 (0.07)

0.09 (0.09)

Spleen

0.30 (0.17)

0.35 (0.16)

0.29 (0.18)

Pancreas

0.03 (0.03)

0.04 (0.03)

0.06 (0.02)

Lung

0.02 (0.01)#

0.06 (0.02)*

0.02 (0.01)

Heart

0.02 (0.01)

0.04 (0.01)

0.04 (0.03)

Stomach†

0.20 (0.31)

0.06 (0.02)

0.07 (0.11)

Bone (Femur)

12.06 (4.60)*

12.20 (4.32)*

4.38 (3.76)

Muscle

0.03 (0.03)

0.04 (0.02)

0.07 (0.07)

Brain

0.03 (0.01)

0.04 (0.03)

0.32 (0.67)

  1. Data are expressed as % injected dose per gram tissue. Each value represents the mean (SD) for from four to seven animals.
  2. †Data are expressed as % injected dose.
  3. Significance of multiple comparison was determined using a one-way ANOVA followed by Tukey’s post hoc test (*p < 0.05 vs. Zn-InsP6, #p < 0.05 vs. InsP6).
Back to article page